Form 8-K - Current report:
SEC Accession No. 0001185185-25-001326
Filing Date
2025-10-01
Accepted
2025-10-01 16:40:35
Documents
14
Period of Report
2025-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K igc8k100125.htm   iXBRL 8-K 34352
2 EXHIBIT 10.1 igcex10-1.htm EX-10.1 36736
3 GRAPHIC image_001.jpg GRAPHIC 1870
  Complete submission text file 0001185185-25-001326.txt   250358

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE igc-20251001.xsd EX-101.SCH 3010
5 XBRL LABEL FILE igc-20251001_lab.xml EX-101.LAB 34235
6 XBRL PRESENTATION FILE igc-20251001_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT igc8k100125_htm.xml XML 3538
Mailing Address 10224 FALLS ROAD POTOMAC MD 20854
Business Address 10224 FALLS ROAD POTOMAC MD 20854 301-529-4996
IGC Pharma, Inc. (Filer) CIK: 0001326205 (see all company filings)

EIN.: 202760393 | State of Incorp.: MD | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-32830 | Film No.: 251365176
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)